Search results
Author(s):
Yugo Yamashita
Added:
7 months ago
ESC 23 — In this concise interview, Dr Yugo Yamashita (Kyoto University Graduate School of Medicine, JP) reveals the findings of the ONCO DVT Study (NCT03895502).
The ONCO DVT study (Takeshi Morimoto) aimed to determine the ideal duration of anticoagulation therapy with the direct oral anticoagulant (DOAC) edoxaban for the treatment of isolated distal deep vein thrombosis (IDDVT) in patients…
View more
Author(s):
Julia Sikorska
,
James Uprichard
Added:
3 years ago
For more than 50 years, oral vitamin K antagonists (VKAs) were the choice of anticoagulant for the long-term treatment and prevention of arterial and venous thromboembolic events (VTE). VKA treatment is safe and effective, if a high time in therapeutic range is achieved. However, achieving a stable, therapeutic international normalised ratio can prove challenging in the context of drug and food…
View more
Author(s):
Daniel TT Chong
,
Felicita Andreotti
,
Peter Verhamme
,
et al
Added:
2 years ago
Author(s):
Antoni Martínez-Rubio
,
Gheorghe-Andrei Dan
Added:
3 years ago
Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?
The novel direct-acting oral anticoagulants (NOACs) apixaban, dabigatran, edoxaban and rivaroxaban overcome most drawbacks of vitamin K antagonists and have proven efficacious and safe in well-designed multicentre randomised clinical trials.1–4 Furthermore, the…
View more
Author(s):
Han Naung Tun
,
May Thu Kyaw
,
Erik Rafflenbeul
,
et al
Added:
1 year ago
Author(s):
Hani Essa
,
Gregory YH Lip
Added:
2 years ago
Author(s):
Pierluigi Merella
,
Giuseppe Talanas
,
Giovanni Lorenzoni
,
et al
Added:
6 months ago
Author(s):
Leonardo Guimaraes
,
David del Val
,
Sebastien Bergeron
,
et al
Added:
3 years ago
Major advances in heart failure (HF) management have been achieved over the past three decades, yet it remains a syndrome with high morbidity and mortality, poor quality of life and high healthcare costs. Despite all advances in medical/device therapy, many HF patients continue to deteriorate, leading to poor quality of life and high rehospitalisation and mortality rates.1 The recent European…
View more
Author(s):
Zaki Akhtar
,
Lisa WM Leung
,
Christos Kontogiannis
,
et al
Added:
2 years ago
Author(s):
Emmanuel Sorbets
,
Philippe Gabriel Steg
Added:
3 years ago
Despite improvements in the management of coronary artery disease over the last decades, ischaemic heart disease remains the leading cause of mortality worldwide and the leading cause of premature death.1,2 Patients with chronic coronary syndromes (CCS) encompass a heterogeneous population, including those with demonstrable coronary artery disease by anatomical testing or evidence of ischaemia,…
View more